Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne-Marie Cleton-Jansen

Showing results (111-120 of 127) with videos related to

Pageof 13
Sort By:
Ebiomedicine|March 19, 2025
Clinical outcomes and genomic profiles of MAP2K1-mutated primary cutaneous melanocytic tumoursChiel F Ebbelaar, Anne M L Jansen, Leonie C M Speet, et al.
Head and Neck Pathology|December 22, 2025
Molecular Analysis in Salivary Gland Tumors: Exploring the Diagnostic and Clinical Impact of Comprehensive Next Generation RNA Sequencing ("SalvGlandDx v2")Kimberly S T Burghout, Jeroen N van Rossem, Sylvia L van Egmond, et al.
The Journal of Molecular Diagnostics : JMD|July 30, 2023
Formalin-Fixed, Paraffin-Embedded-Targeted Locus Capture: A Next-Generation Sequencing Technology for Accurate DNA-Based Gene Fusion Detection in Bone and Soft Tissue TumorsEllen Stelloo, Ruud W J Meijers, Joost F Swennenhuis, et al.
Journal of Adolescent and Young Adult Oncology|January 27, 2016
Workshop Report on the European Bone Sarcoma Networking Meeting: Integration of Clinical Trials with Tumor BiologyDavid M Thomas, Miriam Wilhelm, Anne-Marie Cleton-Jansen, et al.
Oncotarget|April 21, 2015
Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell linesJohnny Suijker, Jan Oosting, Annemarie Koornneef, et al.
Cancer Research|August 17, 2002
CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3Marina Kochetkova, Olivia L D McKenzie, Anthony J Bais, et al.
Cancer Research|September 19, 2007
Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancerJeroen T Buijs, Nico V Henriquez, Petra G M van Overveld, et al.
BMC Cancer|June 7, 2022
Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)David J Barnes, Peter Dutton, Øyvind Bruland, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2020
Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA SequencingDanielle Cohen, Liesbeth M Hondelink, Nienke Solleveld-Westerink, et al.
Cancer Research|January 10, 2002
Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificityGalina N Filippova, Chen-Feng Qi, Jonathan E Ulmer, et al.
Pageof 13

Showing results (111-120 of 127) with videos related to

Sort By:
Pageof 13
Ebiomedicine|March 19, 2025
Clinical outcomes and genomic profiles of MAP2K1-mutated primary cutaneous melanocytic tumoursChiel F Ebbelaar, Anne M L Jansen, Leonie C M Speet, et al.
Head and Neck Pathology|December 22, 2025
Molecular Analysis in Salivary Gland Tumors: Exploring the Diagnostic and Clinical Impact of Comprehensive Next Generation RNA Sequencing ("SalvGlandDx v2")Kimberly S T Burghout, Jeroen N van Rossem, Sylvia L van Egmond, et al.
The Journal of Molecular Diagnostics : JMD|July 30, 2023
Formalin-Fixed, Paraffin-Embedded-Targeted Locus Capture: A Next-Generation Sequencing Technology for Accurate DNA-Based Gene Fusion Detection in Bone and Soft Tissue TumorsEllen Stelloo, Ruud W J Meijers, Joost F Swennenhuis, et al.
Journal of Adolescent and Young Adult Oncology|January 27, 2016
Workshop Report on the European Bone Sarcoma Networking Meeting: Integration of Clinical Trials with Tumor BiologyDavid M Thomas, Miriam Wilhelm, Anne-Marie Cleton-Jansen, et al.
Oncotarget|April 21, 2015
Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell linesJohnny Suijker, Jan Oosting, Annemarie Koornneef, et al.
Cancer Research|August 17, 2002
CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3Marina Kochetkova, Olivia L D McKenzie, Anthony J Bais, et al.
Cancer Research|September 19, 2007
Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancerJeroen T Buijs, Nico V Henriquez, Petra G M van Overveld, et al.
BMC Cancer|June 7, 2022
Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)David J Barnes, Peter Dutton, Øyvind Bruland, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2020
Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA SequencingDanielle Cohen, Liesbeth M Hondelink, Nienke Solleveld-Westerink, et al.
Cancer Research|January 10, 2002
Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificityGalina N Filippova, Chen-Feng Qi, Jonathan E Ulmer, et al.
Pageof 13